AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer

Bibliographic Details
Main Authors: Gianni, L., Romieu, G., Lichinister, M., Serrano, S., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, Arlene, Lipatov, O., Chan, S., Wardley, A., Greil, R., Moore, N., Prot, S., Pallaud, C., Semiglazov, V.
Format: Journal Article
Published: American Society of Clinical Oncology 2013
Online Access:http://hdl.handle.net/20.500.11937/4315

Internet

http://hdl.handle.net/20.500.11937/4315

Similar Items